Inorganic Chemistry
Article
1
(2H, t, J = 7.2 Hz, NCH2), 1.88−1.83 (2H, m, CH3CH2CH2), 1.40−
1.35 (2H, m, CH3CH2), 0.93 (3H, t, J = 7.6 Hz, CH3) ppm. 13C NMR
(DMSO-d6): δ 198.9 (CO), 198.0 (CO) 190.0 (NCN), 189.2 (CO),
153.2 (pyridyl CH), 152.6 (pyridyl quat C), 142.3 (pyridyl CH), 124.0
(pyridyl CH), 124.0 (imidazoyl CH), 117.5 (imidazoyl CH), 112.8
(pyridyl CH), 51.0 (NCH2), 32.7 (CH2CH2CH3), 19.1 (CH2CH3),
13.6 (CH3) ppm. ATR-IR: ν 3937 w, 3775 w, 3164 w, 3114 w, 3092 w,
3060 w, 3030 w, 2964 w, 2935 w, 2864 w, 2017 s (CO), 1918 s (CO),
1871 s (CO), 1710 w, 1615 w, 1575 w, 1558 w, 1487 m, 1464 w, 1450
w, 1429 w, 1384 w, 1370 w, 1331 w, 1288 w, 1263 w, 1249 w, 1197 w,
1159 w, 1146 w, 1128 w, 1107 w, 1091 w, 1033 w, 1022 w, 1001 w,
910 w, 886 w, 856 w, 778 w, 754 w, 702 w, 691 w cm−1.
39.16; H, 2.79; N, 6.85. Found: C, 39.22; H, 2.62; N, 6.79. H NMR
(CDCl3): δ 8.92 (1H, d, J = 6.0 Hz, pyridyl CH), 8.08−8.03 (1H, m,
pyridyl CH), 7.77 (1H, d, J = 2.4 Hz, imidazoyl CH), 7.64 (1H, d, J =
8.0 Hz, pyridyl CH), 7.33−7.31 (1H, m, pyridyl CH), 7.07−7.06 (3H,
m, imidazoyl CH, mesityl CH), 2.37 (3H, s, 4-mesityl CH3), 2.29 (3H,
s, 2,6-mesityl CH3), 2.13 (3H, s, 2,6-mesityl CH3) ppm. 13C NMR
(CDCl3): δ 196.9 (CO), 195.9 (CO), 194.2 (NCN), 188.2 (CO),
154.3 (pyridyl CH), 153.2 (pyridyl quat C), 140.7 (pyridyl CH), 140.3
(4-mesityl C), 136.2 (2,6-mesityl C), 134.8 (2,6-mesityl C), 129.8 (2,5-
mesityl CH), 129.3 (2,5-mesityl CH), 124.4 (imidazoyl CH), 123.5
(pyridyl CH), 116.3 (imidazoyl CH), 111.7 (pyridyl CH), 21.3 (4-
mesityl CH3), 19.0 (2,6-mesityl CH3), 17.8 (2,6-mesityl CH3) ppm.
ATR-IR: ν 3919 w, 3169 w, 3148 w, 3117 w, 3091 w, 3039 w, 2977 w,
2923 w, 2856 w, 2407 w, 2011 s (CO), 1918 s (CO), 1870 s (CO),
1616 m, 1575 w, 1558 w, 1484 m, 1453 w, 1439 w, 1419 w, 1378 w,
1342 w, 1314 w, 1266 w, 1159 w, 1135 w, 1111 w, 1093 w, 1083 w,
1038 w, 977 w, 953 w, 934 w, 872 w, 848 w, 768 w, 747 w, 720 w, 700
w cm−1.
Synthesis of 1Br. A suspension of [Re(CO)5Br] (445 mg, 1.09
mmol), 1-butyl-3-(2-pyridyl)imidazolium bromide (305 mg, 1.08
mmol), and triethylamine (1.5 mL, 10.8 mmol) in toluene (ca. 10
mL) was heated at reflux for 2 days. The resulting mixture was cooled
to room temperature, water (ca. 5 mL) and hexanes (ca. 7 mL) were
added, and eventually the hexanes layer was removed. The aqueous
layer was then extracted with dichloromethane, and the organic phase
was collected, dried over MgSO4, and evaporated to dryness. The
crude product was then purified by flash column chromatography on
deactivated acidic alumina with dichloromethane as the eluting solvent
(327 mg, 55%). Mp: 192 °C dec. Anal. Calcd for C15H15N3O3ReBr: C,
Synthesis of 3Br. The target complex was prepared by following
the same procedure as for 1Br, using 1-(2-pyrimidyl)-3-(2,4,6-
trimethylphenyl)imidazolium hexafluorophosphate as the starting
imidazolium salt (46 mg, 58%). Mp: 277 °C dec. Anal. Calcd for
C19H16BrN4O31Re: C, 37.14; H, 2.62; N, 9.12. Found: C, 37.45; H,
2.66; N, 8.94. H NMR (DMSO-d6): δ 9.24−9.22 (1H, m, pyrimidyl
H6), 9.15−9.13 (1H, m, pyrimidyl H4), 8.45 (1H, d, J = 2.0 Hz,
imidazoyl CH), 7.76 (1H, d, J = 2.4 Hz, imidazoyl CH), 7.64 (1H, t, J
= 5.2 Hz, pyrimidyl H5), 7.13 (1H, s, mesityl CH), 7.10 (1H, s, mesityl
CH), 2.33 (1H, s, CH3), 2.17 (1H, s, CH3), 2.07 (1H, s, CH3) ppm.
13C NMR (100 MHz, DMSO-d6): δ 196.7 (CO), 194.9 (CO), 191.2
(NCN), 188.1 (CO), 163.1 (pyrimidyl CH), 161.0 (pyrimidyl CH),
157.7 (pyrimidyl quat C), 139.2 (phenyl quat C), 135.3 (phenyl quat
C), 134.8 (phenyl quat C), 134.4 (phenyl quat C), 129.0 (phenyl CH),
128.8 (phenyl CH), 125.4 (imidazoyl CH), 120.8 (pyrimidyl CH; C5),
118.6 (imidazoyl CH), 20.7 (CH3), 18.1 (CH3), 17.1 (CH3) ppm.
ATR-IR: ν 3926 w, 3685 w, 3676 w, 3182 w, 2988 m, 2973 m, 2912 m,
2902 m, 2747 w, 2410 w, 2324 w, 2489 w, 2012 s (CO), 1921 s (CO),
1883 s (CO), 1595 m, 1568 w, 1557 w, 1512, 1470 m, 1449 m, 1411
w, 1394 w, 1379 w, 1343 w, 1306 w, 1257 w, 1197 w, 1168 w, 1139 w,
1058 w, 1028 w, 978 w, 963 w, 934 w, 848 w, 809 w, 788 w, 744 w,
699 w, 655 w cm−1.
1
32.67; H, 2.74; N, 7.62. Found: C, 32.69; H, 2.71; N, 7.65. H NMR
(CDCl3): δ 8.90 (1H, d, J = 5.6 Hz, pyridyl H6), 8.00 (1H, dd, J = 1.6
Hz, J = 8.0 Hz, pyridyl CH), 7.57−7.56 (2H, m, imidazoyl CH and
pyridyl CH), 7.29 (1H, dd, J = 1.6 Hz, J = 6.8 Hz, pyridyl CH), 7.08
(1H, d, J = 2.4 Hz, imidazoyl CH), 4.35−4.23 (2H, m, NCH2), 2.04−
1.92 (2H, m, CH2CH2CH2), 1.51−1.46 (2H, m, CH3CH2) 1.01 (3H,
t, J = 7.6 Hz, CH3) ppm. 13C NMR (CDCl3): δ 197.3 (CO), 196.8
(CO), 193.0 (NCN), 188.0 (CO), 153.9 (pyridyl CH), 152.9 (pyridyl
quat C), 140.7 (pyridyl CH), 123.2 (pyridyl CH), 123.1 (imidazoyl
CH), 115.8 (imidazoyl CH), 111.5 (pyridyl CH), 52.4 (NCH2), 33.0
(CH2CH2CH3), 19.8 (CH2CH3), 13.7 (CH3) ppm. ATR-IR: ν 3905 w,
3748 w, 3164 w, 3118 w, 3095 w, 3067 w, 3039 w, 2964 w, 2942 w,
2867 w, 2014 s (CO), 1915 s (CO), 1887 s (CO), 1681 w, 1615 m,
1578 w, 1489 m, 1456 m, 1430 m, 1386 w, 1375 w, 1364 w, 1331 m,
1314 w, 1299 w, 1257 w, 1197 w, 1166 w, 1144 w, 1130 w, 1103 w,
1091 w, 1022 w, 1006 w, 958 w, 908 w, 892 w, 780 w, 747 w, 732 w,
704 w, 690 w cm−1.
Synthesis of 2Cl. The target complex was prepared following the
same procedure reported for 1Br, but starting from [Re(CO)5Cl],
using 1-(2-pyridyl)-3-(2,4,6-trimethylphenyl)imidazolium chloride as
the starting imidazolium salt (32 mg, 49%). Crystals suitable for a
single-crystal X-ray diffraction study were grown from slow
evaporation of an acetonitrile solution of 2Cl. Mp: 235 °C dec.
Anal. Calcd for C20H17N3O3ReCl: C, 42.21; H, 3.01; N, 7.39. Found:
Synthesis of 4Cl. The target complex was prepared following the
same procedure as for 1Br, but starting from [Re(CO)5Cl], with 1-(2-
pyrimidyl)-3-(phenyl)imidazolium chloride as the starting imidazolium
salt (43 mg, 58%). Crystals suitable for a single-crystal X-ray diffraction
study were grown from slow evaporation of an acetonitrile solution of
4Cl. Mp: 249 °C dec. Anal. Calcd for C16H10ClN4O3Re: C, 36.40; H,
1.91; N, 10.61. Found: C, 36.10; H, 1.94; N, 10.42. 1H NMR (DMSO-
d6): δ 9.27−9.25 (1H, m, pyrimidyl H6), 9.17−9.16 (1H, m, pyrimidyl
H4), 8.42 (1H, d, J = 2.0 Hz, imidazoyl CH), 8.01 (1H, d, J = 2.0 Hz,
imidazoyl CH), 7.71−7.61 (6H, m, pyrimidyl H5, phenyl ortho-H,
meta-H, para-H) ppm. 13C NMR (DMSO-d6): δ 197.3 (CO), 196.5
(CO), 190.4 (NCN), 188.6 (CO), 162.8 (pyrimidyl CH), 161.2
(pyrimidyl CH), 157.7 (pyrimidyl quat C), 138.6 (phenyl quat C),
129.7 (phenyl CH), 129.6 (2 × phenyl CH), 126.0 (2 × phenyl CH),
125.4 (imidazoyl CH), 121.0 (pyrimidyl CH), 118.3 (imidazoyl CH)
ppm. ATR-IR: ν 3175 w, 3145 w, 3067 w, 2020 s (CO), 1913 s (CO),
1865 s (CO), 1596 m, 1568 m, 1500 w, 1470 m, 1446 m, 1416 m,
1378 m, 1346 m, 1320 m, 1301 w, 1263 m, 1199 w, 1144 w, 1097 w,
1070 w, 1022 w, 979 w, 951 w, 817 w, 787 w, 761 w, 746 m, 690 m,
633 w, 618 w, 527 w cm−1.
Synthesis of 4Br. The target complex was prepared following the
same procedure as for 1Br using 1-(2-pyrimidyl)-3-phenylimidazolium
hexafluorophosphate as the starting imidazolium salt (28 mg, 35%).
Crystals suitable for a single-crystal X-ray diffraction study were grown
from slow evaporation of an acetonitrile solution of 4Br. Mp: 200 °C
dec. Anal. Calcd for C16H10BrN4O3Re·0.5CH2Cl2: C, 32.23; H, 1.80;
N, 9.11. Found: C, 32.63; H, 1.80; N, 8.77 (despite several attempts,
the complex was always isolated as a solvated species; the presence of
dichloromethane was also confirmed via 1H NMR). 1H NMR
(DMSO-d6): δ 9.27−9.25 (1H, m, pyrimidyl H6), 9.16−9.14 (1H,
1
C, 42.03; H, 2.89; N, 7.21. H NMR (CDCl3): δ 8.92 (1H, d, J = 7.8
Hz, pyridyl CH), 8.07 (1H, dd, J = 1.6 Hz, J = 8.0 Hz, pyridyl CH),
7.75 (1H, d, J = 2.4 Hz, imidazoyl CH), 7.64 (1H, d, J = 8.4 Hz,
pyridyl CH), 7.64 (1H, d, J = 8.4 Hz, pyridyl CH), 7.34 (1H, dd, J =
1.2 Hz, J = 6.6 Hz, pyridyl CH), 7.07−7.06 (3H, m, imidazoyl CH,
mesityl CH), 2.38 (3H, s, 4-mesityl CH3), 2.25 (3H, s, 2,6-mesityl
CH3), 2.14 (3H, s, 2,6-mesityl CH3) ppm. 13C NMR (CDCl3): δ 197.7
(CO), 196.8 (CO), 194.7 (NCN), 188.7 (CO), 154.2 (pyridyl CH),
153.3 (pyridyl quat C), 140.8 (pyridyl CH), 140.3 (4-mesityl quat C),
136.3 (2,6-mesityl quat C), 135.2 (1-mesityl quat C), 134.8 (2,6-
mesityl quat C), 129.8 (3,5-mesityl CH), 129.3 (3,5-mesityl CH),
124.3 (imidazoyl CH), 123.6 (pyridyl CH), 116.3 (imidazoyl CH),
111.7 (pyridyl CH), 21.3 (4-mesityl CH3), 18.5 (2,6-mesityl CH3),
17.8 (2,6-mesityl CH3) ppm. ATR-IR: ν 3089 w, 2924 w, 2010 s
(CO), 1909 s (CO), 1867 s (CO), 1615 m, 1544 w, 1515 w, 1483 m,
1453 w, 1421 m, 1379 w, 1343 w, 1315 w, 1265 w, 1237 w, 1160 w,
1135 w, 1036 w, 910 w, 850 w, 771 w, 703 w cm−1.
Synthesis of 2Br. The target complex was prepared following the
same procedure as for 1Br, using 1-(2-pyridyl)-3-(2,4,6-
trimethylphenyl)imidazolium bromide as the starting imidazolium
salt (199 mg, 66%). Crystals suitable for a single-crystal X-ray
diffraction study were grown from slow evaporation of an acetonitrile
solution of 2Br. Mp: 243 °C dec. Anal. Calcd for C20H17N3O3ReBr: C,
3632
dx.doi.org/10.1021/ic403138a | Inorg. Chem. 2014, 53, 3629−3641